Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H7O6P |
| Molecular Weight | 218.1006 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(OP(O)(O)=O)C=CC=C1
InChI
InChIKey=FFKUDWZICMJVPA-UHFFFAOYSA-N
InChI=1S/C7H7O6P/c8-7(9)5-3-1-2-4-6(5)13-14(10,11)12/h1-4H,(H,8,9)(H2,10,11,12)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21797253Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3264273 | https://www.ncbi.nlm.nih.gov/pubmed/8008964 | https://www.ncbi.nlm.nih.gov/pubmed/7325717 | https://www.ncbi.nlm.nih.gov/pubmed/7012470 | https://www.ncbi.nlm.nih.gov/pubmed/3163974
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21797253
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3264273 | https://www.ncbi.nlm.nih.gov/pubmed/8008964 | https://www.ncbi.nlm.nih.gov/pubmed/7325717 | https://www.ncbi.nlm.nih.gov/pubmed/7012470 | https://www.ncbi.nlm.nih.gov/pubmed/3163974
Fosfosal (2-phosphonoxybenzoic acid) is a O-phosphorylated derivative of salicylic acid used in analgesic and anti-inflammatory therapy. Fosfosal showed analgesic effect in the acetic acid-induced writhing and in the hot plate tests in mice, and showed antiinflammatory effect in the xylene induced mice ears swelling and in acetic acid induced increased vascular permeability tests in mice. Both the effects had no significant differences between fosfosal and aspirin, but the former had less stomach irritation.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11965374 |
2.0 mM [IC50] | ||
Target ID: CHEMBL5817 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11965374 |
17.4 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
276 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3264273 |
2400 mg 3 times / day steady-state, oral dose: 2400 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FOSFOSAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. | 2006-12 |
|
| Injectable and self-curing composites of acrylic/bioactive glass and drug systems. A histomorphometric analysis of the behaviour in rabbits. | 2006-03 |
|
| Injectable self-curing bioactive acrylic-glass composites charged with specific anti-inflammatory/analgesic agent. | 2004-05 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7012470
The daily dose of fosfosal was 1 gram three times a day, once every 6-8 hours.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID9045394
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
4265
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
1244
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
C65760
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
6064-83-1
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL287275
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
124X2V25W4
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
227-993-5
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
3418
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
100000080459
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
46475
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
C000380
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
SUB07799MIG
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | |||
|
m5552
Created by
admin on Mon Mar 31 18:33:26 GMT 2025 , Edited by admin on Mon Mar 31 18:33:26 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY